Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC).

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Enric Carcereny CostaPere Gascón Vilaplana

Abstract

Lung cancer is a leading cause of death worldwide and, although some progress has been made in its treatment, the results remain poor. Better knowledge in tumour biology has allowed us to design anti-target drugs and incorporate them in the treatment of non-small-cell lung cancer (NSCLC). One of the most widely used targeted approaches in this type of tumour has been the inhibition of angiogenesis. Several strategies blocking the VEGF pathway, either at the ligand or recepor level, have been studied and developed. In this review, we present an up-to-date analysis of the current inhibitors of angiogenesis in the treatment of NSCLC.

References

Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·D M ParkinP Pisani
Jun 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jianzhong HuangJessica J Kandel
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne L ThomasWilliam P Steward
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S N HoldenH I Hurwitz
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiGiorgio V Scagliotti

❮ Previous
Next ❯

Citations

Nov 19, 2009·Growth Factors·Mikael MikkoC Magnus Sköld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
A Abad
Current Medicinal Chemistry
Pilar SerraBeatriz de Pascual-Teresa
© 2022 Meta ULC. All rights reserved